Wenli Zuo Xinghu Zhu Jingke Yang Zhenyang Mei Mei Deng Quande Lin Yongping Song Qingsong Yin
10.1097/MD.0000000000005787
Medicine (Baltimore)
2017 Jan;96(1):e5787.
CC BY-SA
https://pubmed.ncbi.nlm.nih.gov/28072730/
Adenocarcinoma / drug therapy Adenocarcinoma / pathology Adenocarcinoma / surgery Bortezomib / administration & dosage Lung Neoplasms / drug therapy Lung Neoplasms / pathology Lung Neoplasms / surgery Lung / diagnostic imaging Lung / pathology Multiple Myeloma / drug therapy Multiple Myeloma / pathology Thalidomide / analogs & derivatives Thoracic Vertebrae / diagnostic imaging Thoracic Vertebrae / pathology
Adenocarcinoma / drug therapy Adenocarcinoma / pathology Adenocarcinoma / surgery Bortezomib / administration & dosage Lung Neoplasms / drug therapy Lung Neoplasms / pathology Lung Neoplasms / surgery Lung / diagnostic imaging Lung / pathology Multiple Myeloma / drug therapy Multiple Myeloma / pathology Thalidomide / analogs & derivatives Thoracic Vertebrae / diagnostic imaging Thoracic Vertebrae / pathology Case Reports Aged Antineoplastic Agents / administration & dosage Antineoplastic Combined Chemotherapy Protocols / administration & dosage Biopsy, Needle / methods Humans Lenalidomide Magnetic Resonance Imaging / methods Male Neoplasms, Multiple Primary Positron Emission Tomography Computed Tomography Thalidomide / administration & dosage Treatment Outcome Antineoplastic Agents Thalidomide Bortezomib Lenalidomide
PMC5228690
28072730
Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report
2017